Inspire’s neurostimulator for obstructive sleep apnoea therapy gains FDA approval
According to GlobalData, the market for neurological devices was valued at $12.5bn in 2023 and is expected to grow by a CAGR of 4.60% to reach $20.9bn by 2033.
Neurology
Orlando Health uses Abbott’s rapid TBI blood test
Neuralink implants second paralysed patient with brain-chip
MMI successfully trials Symani surgical robot in neurosurgery
Biogen, Beckman Coulter and Fujirebio partner to develop Alzheimer’s Tau blood test
Cognito’s sensory stimulation device slows decline in Alzheimer’s
TMS in California will have Medicaid coverage for major depressive disorder patients
PathMaker secures funding from US DoD for neuromodulation ALS trial
